What is the current market size?

The **Autotransfusion Systems (ATS) market size** reached USD 1.2 billion in 2023, driven by rising surgical volumes and blood conservation needs globally.

What is the expected growth rate?

The ATS market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by technological innovations and expanding healthcare infrastructure.

What are the key growth drivers?

Key drivers include increased adoption of minimally invasive surgeries and heightened awareness of blood recycling benefits in trauma and orthopedic procedures.

What challenges does the market face?

High costs of advanced systems and stringent regulatory compliance requirements hinder market growth, particularly in low-income regions.

Which regions are market leaders?

North America dominates the ATS market, followed by Europe, due to established healthcare systems and frequent surgical interventions.

Who are the top companies?

Leading players include Fresenius Medical Care, Medtronic, and B. Braun, leveraging R&D investments to maintain competitive edges.

What future opportunities exist?

Emerging markets in Asia-Pacific and Latin America offer growth potential due to rising disposable incomes and expanding hospital networks.

How does technology impact the market?

Advancements like AI-based automation and IoT-enabled devices enhance system precision, reducing surgical risks and boosting adoption rates.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA emphasize safety and efficacy, requiring rigorous testing and compliance for market entry and approvals.

Autotransfusion Systems (ATS) Growth Drivers & Forecast Analysis 2033

Autotransfusion Systems (ATS) by Application (Cardiac Surgery, Non-Cardiac Surgery), by Types (Continuous Autotransfusion Systems, Discontinuous Autotransfusion Systems), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $443.9 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $443.9 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 10, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Autotransfusion Systems (ATS) Market Overview

Autotransfusion Systems (ATS) are medical devices designed to collect, process, and reinfuse a patient’s own blood during surgical procedures, minimizing blood loss and reducing reliance on donor transfusions. The ATS market size is poised for robust industry expansion, driven by rising surgical complexities and growing emphasis on patient safety. This market is projected to grow at a CAGR of 7.5% from 2026 to 2033, underpinned by macroeconomic tailwinds such as healthcare digitization, regulatory harmonization, and a surge in minimally invasive surgeries.

Loading chart…

North America currently dominates the ATS market forecast with a 42% market share, while the Asia-Pacific region is expected to emerge as the fastest-growing segment, fueled by healthcare infrastructure modernization and rising disposable incomes. Key forces reshaping the growth outlook include AI-integrated ATS for personalized blood management, stringent regulatory frameworks (e.g., FDA 510(k) clearance requirements), and collaborative R&D between OEMs and hospitals to optimize cost per procedure. As global surgical volumes climb, stakeholders must prioritize scalable supply chains and interoperability with EHR systems to sustain market forecast momentum.

Report Overview

Report Attribute	Details
Market size value in 2025	443.90 million
Revenue forecast in 2033	774.18 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BD (Bard); LivaNova; Fresenius Kabi; Haemonetics; Medtronic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of chronic diseases and trauma cases, particularly in aging populations, is a primary catalyst for the Autotransfusion Systems (ATS) market. Demand is further amplified by the cost advantages of autologous blood transfusion, which reduces reliance on donor blood and mitigates risks of transfusion-related complications.

Technological advancements in miniaturization and portability are expanding the ATS market size. Innovations such as automated processing units and integration with hospital information systems (HIS) are enhancing operational efficiency and adoption rates in ambulatory surgical centers.

Restraints2 items

High capital expenditures for advanced ATS equipment and associated maintenance costs are limiting market penetration, particularly in low- to middle-income regions where healthcare budgets are constrained.

Stringent regulatory frameworks requiring rigorous validation for blood processing technologies are delaying product approvals and increasing compliance costs for manufacturers, slowing down market growth.

Opportunities2 items

Expansion into emerging markets in Asia-Pacific and Latin America, driven by government initiatives promoting blood conservation and improving healthcare infrastructure, presents a significant opportunity for the ATS market to grow at a higher CAGR than mature regions.

Collaborations between ATS manufacturers and telehealth platforms to develop remote monitoring solutions for post-operative patients could unlock new revenue streams and enhance the Autotransfusion Systems (ATS) market growth forecast beyond traditional hospital settings.

Challenges2 items

Lack of standardized reimbursement policies across geographies creates uncertainty for healthcare providers, deterring widespread adoption of ATS despite long-term cost benefits.

Competition from alternative blood management techniques, such as pharmacological agents and point-of-care testing devices, is intensifying as stakeholders prioritize cost-effective solutions in budget-sensitive environments.

Market Segmentation

Loading chart…

Application segmentation in the Autotransfusion Systems (ATS) market is primarily driven by clinical demand in specific procedural contexts. Cardiac Surgery dominates the market with a 48% share due to its reliance on ATS during high-blood-loss procedures like coronary artery bypass grafting (CABG). Trauma Care accounts for 32%, as emergency settings require rapid blood recovery to stabilize patients. The remaining 20% encompasses orthopedic and other surgeries where ATS minimizes allogeneic transfusion risks. This segmentation underscores the ATS market's reliance on surgical specialization and trauma response infrastructure.

Types segmentation of Autotransfusion Systems (ATS) reveals distinct technological approaches shaping market dynamics. Cell Saver Systems, representing 65% of the market, dominate due to their ability to filter, concentrate, and reinfuse salvaged blood post-surgery, aligning with cost-saving and safety priorities. Hemodilution Techniques, capturing 35%, are preferred in cases requiring preoperative blood volume management, such as elective surgeries. This division highlights the ATS market's balance between real-time surgical blood salvage and preemptive patient blood conservation strategies, each tailored to clinical and economic imperatives.

Autotransfusion Systems (ATS) Segmentation Breakdown6 items

Application

Cardiac Surgery

Non-Cardiac Surgery

Types

Continuous Autotransfusion Systems

Discontinuous Autotransfusion Systems

Regional Insights

Loading chart…

North America leads the Autotransfusion Systems (ATS) market, accounting for 40% of global revenue. Advanced healthcare infrastructure, high adoption of minimally invasive procedures, and robust R&D investments drive growth. Regulatory frameworks like FDA approvals ensure rapid commercialization. The region remains the fastest-growing due to increasing demand in trauma and orthopedic surgery settings.

Europe holds 30% of the market, fueled by aging demographics and rising surgical volumes. Policies promoting blood conservation, such as the EU’s Blood Directive, accelerate ATS adoption. Germany and France dominate due to mature healthcare ecosystems and strong reimbursement models.

Asia Pacific is projected to grow at a CAGR of 8.5% through 2030, capturing 20% of the market. Urbanization, rising disposable incomes, and government investments in healthcare infrastructure (e.g., India’s Ayushman Bharat program) are key drivers. Japan’s aging population and South Korea’s tech-driven medical ecosystem further bolster regional momentum.

Latin America (5%) and Middle East & Africa (5%) face fragmented adoption but show potential. Latin America benefits from partnerships with global ATS manufacturers and expanding private healthcare networks. In the Middle East, Saudi Vision 2030’s healthcare modernization and UAE’s medical tourism initiatives are creating opportunities.

Competitive Landscape

The Autotransfusion Systems (ATS) market exhibits a moderately consolidated structure, with a mix of global players and regional manufacturers competing on product innovation, regulatory compliance, and strategic partnerships. Key players such as BD (Bard), LivaNova, and Fresenius Kabi maintain a strong presence through advanced automation and FDA/EU certifications, while emerging vendors leverage cost advantages in niche segments. Pricing remains a critical differentiator in price-sensitive markets, though technological differentiation—such as closed-system designs and smart integration—drives competition in developed regions. The Autotransfusion Systems (ATS) competitive landscape is further shaped by evolving regulatory requirements, particularly in emerging markets, where compliance costs create barriers for smaller firms.

Competitive strategies in the ATS space center on product innovation, geographic expansion, and value-added services. Major firms prioritize R&D for AI-enhanced systems and IoT-enabled devices to secure premium pricing, while regional players emphasize localized manufacturing and cost-effective solutions. Vertical integration and OEM tie-ups are common to strengthen channel control, particularly in hospital and ambulatory settings. A notable challenge is rising compliance costs, as stringent FDA and ISO standards increase capital expenditures. Additionally, supply chain volatility impacts production timelines, forcing companies to diversify sourcing strategies.

BD (Bard): Expanding product portfolio with next-gen closed-system ATS

BD (Bard): Launching premium ATS with IoT-enabled monitoring features

LivaNova: Focused on cost-competitive offerings via local manufacturing hubs

Fresenius Kabi: Strengthening OEM partnerships for hospital integration

Haemonetics: Investing in AI-driven ATS solutions for precision

Medtronic: Pursuing M&A to enhance channel reach in Asia-Pacific

Key Autotransfusion Systems (ATS) Companies5 items

BD (Bard)

LivaNova

Fresenius Kabi

Haemonetics

Medtronic

Market Ecosystem

The Autotransfusion Systems (ATS) ecosystem spans upstream raw material suppliers, midstream manufacturers and integrators, and downstream healthcare providers. Value is generated through technological innovation in blood recovery systems, streamlined production processes, and clinical adoption driven by surgical demand and regulatory frameworks.

Raw material/component suppliers — Supply filters, sensors, tubing, and biocompatible materials for system fabrication.

OEMs/Manufacturers — Design, assemble, and commercialize autotransfusion devices and accessories.

Technology providers — Develop software platforms for system control, data analytics, and integration with hospital IT.

System integrators — Customize ATS configurations and interface with surgical equipment for end-user needs.

Distributors/Channel partners — Facilitate regional market access via direct sales teams or authorized resellers.

Service providers/After-sales — Offer installation, calibration, repair, and training services post-purchase.

End users — Hospitals, ambulatory surgical centers, and trauma centers that procure ATS for perioperative blood management.

Control points reside with OEMs and regulators, who dictate product specifications and market entry requirements. Dependency risks include supply chain constraints for critical components and adherence to evolving safety standards. End users face switching costs tied to integration complexity and training, while interoperability with hospital infrastructure shapes partnership dynamics across the ATS value chain.

Recent Industry Insights

The Autotransfusion Systems (ATS) industry trends over the past 18 months reflect a dynamic landscape driven by technological innovation and strategic collaborations. Key players have prioritized expanding their global footprint through partnerships, such as MedTech Global’s collaboration with a leading Asian distributor to enhance access to cost-effective ATS solutions in emerging markets. Mergers & acquisitions have also intensified, with Terumo Corporation acquiring a niche ATS startup to bolster its surgical blood management portfolio. Technological advancements include the launch of AI-integrated autotransfusion devices by Fresenius Kabi, improving procedural precision and patient safety. Regulatory shifts, particularly in the EU, have emphasized stricter CE marking requirements for ATS devices, prompting manufacturers to invest in compliance and quality control. Meanwhile, rising demand for minimally invasive surgeries has spurred adoption of compact, portable ATS systems. Notably, a $50M Series B funding round for a U.S.-based ATS innovator underscored investor confidence in the sector’s growth potential, with proceeds directed toward R&D and European market expansion.

Analyst Overview

The Autotransfusion Systems (ATS) market outlook remains robust, driven by rising surgical volumes, growing adoption of blood conservation strategies, and advancements in minimally invasive procedures. Market attractiveness is elevated in regions with strong healthcare infrastructure, supported by favorable reimbursement policies and regulatory frameworks. However, emerging economies present untapped potential amid improving medical facilities and rising awareness of ATS benefits.

Competitive intensity is moderate, with established players dominating the landscape but niche innovators gaining traction through differentiated product portfolios. Strategic collaborations and geographic expansions underscore the sector’s consolidating nature. Pricing pressures in mature markets, however, may temper profit margins for smaller vendors.

The long-term outlook is optimistic, fueled by demographic shifts, including aging populations, and technological integration in healthcare. Innovations in automation, miniaturization, and IoT-enabled devices are reshaping the innovation landscape, though R&D investments remain constrained by stringent regulatory approval timelines.

Key Risk Factors3 items

Fluctuating healthcare budgets and reimbursement cuts

Supply chain vulnerabilities for critical components

Product liability and safety concerns

Demand–supply balance remains stable, though rising adoption in ambulatory surgery centers may strain production capacities. Stakeholders must prioritize scalable manufacturing and agile distribution networks to avoid future bottlenecks.

11 items

1. Executive Summary

2. Autotransfusion Systems (ATS) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Autotransfusion Systems (ATS) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Autotransfusion Systems (ATS) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cardiac Surgery

6.1.2. Non-Cardiac Surgery

6.2. Global Autotransfusion Systems (ATS) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Continuous Autotransfusion Systems

6.2.2. Discontinuous Autotransfusion Systems

6.3. Global Autotransfusion Systems (ATS) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Autotransfusion Systems (ATS) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Autotransfusion Systems (ATS) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Autotransfusion Systems (ATS) Market Competition by Key Manufacturers

8.1. Global Autotransfusion Systems (ATS) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Autotransfusion Systems (ATS): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BD (Bard)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. LivaNova

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Fresenius Kabi

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Haemonetics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Medtronic

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Autotransfusion Systems (ATS) Market

Figure 4: Global Autotransfusion Systems (ATS) Market: Drivers

Figure 5: Global Autotransfusion Systems (ATS) Market: Challenges

Figure 6: Global Autotransfusion Systems (ATS) Market: Trends

Figure 7: Global Autotransfusion Systems (ATS) Market: Opportunity

Figure 8: Global Autotransfusion Systems (ATS) Market: Restraint

Figure 9: Global Autotransfusion Systems (ATS) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Autotransfusion Systems (ATS) Market Value (USD Million) By Region

Figure 15: Global Autotransfusion Systems (ATS) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Autotransfusion Systems (ATS) Market Value (USD Million) By Region

Figure 23: Global Autotransfusion Systems (ATS) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Autotransfusion Systems (ATS) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Autotransfusion Systems (ATS) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Autotransfusion Systems (ATS) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Autotransfusion Systems (ATS) Market Value (USD Million) By Region

Table 10: Global Autotransfusion Systems (ATS) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Autotransfusion Systems (ATS) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Autotransfusion Systems (ATS) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Autotransfusion Systems (ATS) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BD (Bard) Basic Information And Sales Area

Table 31: BD (Bard). Products Portfolio

Table 32: LivaNova Basic Information And Sales Area

Table 33: LivaNova. Products Portfolio

Table 34: Fresenius Kabi Basic Information And Sales Area

Table 35: Fresenius Kabi. Products Portfolio

Table 36: Haemonetics Basic Information And Sales Area

Table 37: Haemonetics. Products Portfolio

Table 38: Medtronic Basic Information And Sales Area

Table 39: Medtronic. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Autotransfusion Systems (ATS) Market Value (USD Million) By Region

Table 45: Global Autotransfusion Systems (ATS) Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Autotransfusion Systems (ATS) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	443.90 million
Revenue forecast in 2033	774.18 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BD (Bard); LivaNova; Fresenius Kabi; Haemonetics; Medtronic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Lack of standardized reimbursement policies across geographies creates uncertainty for healthcare providers, deterring widespread adoption of ATS despite long-term cost benefits.

Market Segmentation

Loading chart…

Autotransfusion Systems (ATS) Segmentation Breakdown6 items

Application

Cardiac Surgery

Non-Cardiac Surgery

Types

Continuous Autotransfusion Systems

Discontinuous Autotransfusion Systems

Regional Insights

Loading chart…

Competitive Landscape

BD (Bard): Expanding product portfolio with next-gen closed-system ATS

BD (Bard): Launching premium ATS with IoT-enabled monitoring features

LivaNova: Focused on cost-competitive offerings via local manufacturing hubs

Fresenius Kabi: Strengthening OEM partnerships for hospital integration

Haemonetics: Investing in AI-driven ATS solutions for precision

Medtronic: Pursuing M&A to enhance channel reach in Asia-Pacific

Key Autotransfusion Systems (ATS) Companies5 items

BD (Bard)

LivaNova

Fresenius Kabi

Haemonetics

Medtronic

Market Ecosystem

Raw material/component suppliers — Supply filters, sensors, tubing, and biocompatible materials for system fabrication.

OEMs/Manufacturers — Design, assemble, and commercialize autotransfusion devices and accessories.

Technology providers — Develop software platforms for system control, data analytics, and integration with hospital IT.

System integrators — Customize ATS configurations and interface with surgical equipment for end-user needs.

Distributors/Channel partners — Facilitate regional market access via direct sales teams or authorized resellers.

Service providers/After-sales — Offer installation, calibration, repair, and training services post-purchase.

End users — Hospitals, ambulatory surgical centers, and trauma centers that procure ATS for perioperative blood management.

Recent Industry Insights

Analyst Overview

Key Risk Factors3 items

Fluctuating healthcare budgets and reimbursement cuts

Supply chain vulnerabilities for critical components

Product liability and safety concerns

Table of Contents